This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in
patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include
clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell
carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)